Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. on August 9, 2007. The filing addresses the termination of a material definitive agreement with Theragenex, LLC. Note: The request metadata references "Savara Inc," but the filing text explicitly identifies the registrant as ADVENTRX Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed relates to a contractual dispute:
- Disputed Payment: $500,000 (Second installment of a non-creditable, non-refundable upfront payment).
- Payment Due Date: June 30, 2007.
- Payment Status: Unpaid; Theragenex failed to remit funds.
Material Changes
The primary material change reported is the termination of the License Agreement dated October 20, 2006, between ADVENTRX and Theragenex. This action was taken by ADVENTRX on August 9, 2007, following a material breach by Theragenex. The breach consisted of the failure to make the required $500,000 payment by the June 30, 2007 deadline. ADVENTRX had previously notified Theragenex of this breach on July 3, 2007, and the termination became effective after the 30-day cure period expired.
Outlook, Risks, and Management Commentary
Management Commentary: ADVENTRX intends to pursue all appropriate remedies regarding the terminated agreement, specifically including the right to receive the $500,000 installment that was due.
Risks and Contingencies: The filing highlights a legal and financial contingency involving the collection of the unpaid $500,000. There is a noted history of dispute, as Theragenex had previously purported to terminate the same agreement in May 2007, which ADVENTRX had reported in a prior 8-K.
Investor Verification Checklist
- Verify the current legal status of the $500,000 claim against Theragenex, LLC.
- Confirm whether ADVENTRX has initiated litigation or arbitration to recover the unpaid funds.
- Review the May 24, 2007 Form 8-K to understand the context of Theragenex's prior purported termination.
- Assess the impact of this terminated license agreement on ADVENTRX's overall pipeline and future revenue projections.